Stokes Family Office LLC Cuts Holdings in Eli Lilly and Company (NYSE:LLY)

Stokes Family Office LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 14.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 4,153 shares of the company’s stock after selling 722 shares during the period. Stokes Family Office LLC’s holdings in Eli Lilly and Company were worth $2,421,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bordeaux Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 14.5% during the 4th quarter. Bordeaux Wealth Advisors LLC now owns 695 shares of the company’s stock valued at $405,000 after purchasing an additional 88 shares during the last quarter. Goldstream Capital Management Ltd increased its holdings in Eli Lilly and Company by 190.6% during the fourth quarter. Goldstream Capital Management Ltd now owns 5,685 shares of the company’s stock worth $3,314,000 after buying an additional 3,729 shares during the last quarter. Montis Financial LLC raised its position in Eli Lilly and Company by 9.4% in the fourth quarter. Montis Financial LLC now owns 464 shares of the company’s stock worth $271,000 after acquiring an additional 40 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Eli Lilly and Company by 49.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 8,294 shares of the company’s stock valued at $4,834,000 after acquiring an additional 2,746 shares during the last quarter. Finally, Aveo Capital Partners LLC grew its position in shares of Eli Lilly and Company by 8.2% during the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after acquiring an additional 153 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $20.94 on Friday, hitting $734.97. The company’s stock had a trading volume of 4,535,213 shares, compared to its average volume of 3,087,178. The company has a market capitalization of $698.52 billion, a PE ratio of 108.24, a PEG ratio of 1.57 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The company has a 50-day simple moving average of $761.75 and a 200 day simple moving average of $670.56. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the firm posted $1.62 earnings per share. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. Sell-side analysts forecast that Eli Lilly and Company will post 13.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Truist Financial raised their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.